[1]
|
Agache, I., Beltran, J., Akdis, C., et al. (2020) Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma. A Systematic Review for the EAACI Guidelines—Recommendations on the Use of Biologicals in Severe Asthma. Allergy, 75, 1023-1042.
https://doi.org/10.1111/all.14221
|
[2]
|
中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童过敏性鼻炎诊疗——临床实践指南[J]. 中国实用儿科杂志, 2019, 34(3): 169-175.
|
[3]
|
中华儿科杂志编辑委员会, 中华医学会儿科学分会呼吸学组, 中国医师协会儿科医师分会儿童呼吸专业委员会. 儿童支气管哮喘规范化诊治建议(2020年版) [J]. 中华儿科杂志, 2020, 58(9): 708-717.
|
[4]
|
中华医学会变态反应分会呼吸过敏学组, 中华医学会呼吸病学分会哮喘学组. 中国过敏性哮喘诊治指南(第一版, 2019年) [J]. 中华内科杂志, 2019, 58(9): 636-655.
|
[5]
|
谢利生, 蒋银珠, 李琦. 舌下含服粉尘螨滴剂对儿童变应性鼻炎的免疫治疗效果[J]. 临床耳鼻咽喉头颈外科杂志, 2016, 30(5): 357-360.
|
[6]
|
Virchow, J.C., Backer, V., Kuna, P., et al. (2016) Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults with Allergic Asthma: A Randomized Clinical Trial. JAMA, 315, 1715-1725.
https://doi.org/10.1001/jama.2016.3964
|
[7]
|
Shamji, M.H. and Durham, S.R. (2017) Mechanisms of Allergen Immunotherapy for Inhaled Allergens and Predictive Biomarkers. The Journal of Allergy and Clinical Immunology, 140, 1485-1498.
https://doi.org/10.1016/j.jaci.2017.10.010
|
[8]
|
Pelaia, C., Vatrella, A., Lombardo, N., et al. (2018) Biological Mechanisms Underlying the Clinical Effects of Allergen-Specific Immunotherapy in Asthmatic Children. Expert Opinion on Biological Therapy, 18, 197-204.
https://doi.org/10.1080/14712598.2018.1402003
|
[9]
|
Jutel, M., Agache, I., Bonini, S., et al. (2015) International Consensus on Allergy Immunotherapy. The Journal of Allergy and Clinical Immunology, 136, 556-568. https://doi.org/10.1016/j.jaci.2015.04.047
|
[10]
|
Wang, T., Li, Y., Wang, F., et al. (2017) Nonadherence to Sub-lingual Immunotherapy in Allergic Rhinitis: A Real-Life Analysis. International Forum of Allergy & Rhinology, 7, 389-392. https://doi.org/10.1002/alr.21909
|
[11]
|
Dantzer, J.A. and Wood, R.A. (2018) The Use of Omalizumab in Allergen Immunotherapy. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology, 48, 232-240.
https://doi.org/10.1111/cea.13084
|
[12]
|
Kostadinova, A.I., Willemsen, L.E., Knippels, L.M., et al. (2013) Immu-notherapy—Risk/Benefit in Food Allergy. Pediatric Allergy and Immunology: Official Publication of the European Society of Pediatric Allergy and Immunology, 24, 633-644. https://doi.org/10.1111/pai.12122
|
[13]
|
FitzGerald, J.M., Bleecker, E.R., Nair, P., et al. (2016) Benralizumab, an Anti-Interleukin-5 Receptor α Monoclonal Antibody, as Add-On Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet (London, England), 388, 2128-2141.
https://doi.org/10.1016/S0140-6736(16)31322-8
|
[14]
|
Vos, T., Flaxman, A.D., Naghavi, M., et al. (2012) Years Lived with Disability (YLDs) for 1160 Sequelae of 289 Diseases and Injuries 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet (London, England), 380, 2163-2196. https://doi.org/10.1016/S0140-6736(12)61729-2
|
[15]
|
Licari, A., Castagnoli, R., Brambilla, I., et al. (2018) New Approaches for Identifying and Testing Potential New Anti-Asthma Agents. Expert Opinion on Drug Discovery, 13, 51-63. https://doi.org/10.1080/17460441.2018.1396315
|
[16]
|
Licari, A., Castagnoli, R., Panfili, E., et al. (2017) An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases. Current Respiratory Medicine Reviews, 13, 22-29. https://doi.org/10.2174/1573398X13666170616110738
|
[17]
|
Stelmach, I., Majak, P., Jerzyńska, J., et al. (2015) Children with Severe Asthma Can Start Allergen Immunotherapy after Controlling Asthma with Omalizumab: A Case Series from Poland. Archives of Medical Science: AMS, 11, 901-904. https://doi.org/10.5114/aoms.2015.48546
|
[18]
|
Hambly, N. and Nair, P. (2014) Monoclonal Antibodies for the Treatment of Refractory Asthma. Current Opinion in Pulmonary Medicine, 20, 87-94. https://doi.org/10.1097/MCP.0000000000000007
|
[19]
|
Pelaia, C., Calabrese, C., Terracciano, R., et al. (2018) Omalizumab, the First Available Antibody for Biological Treatment of Severe Asthma: More than a Decade of Real-Life Effectiveness. Therapeutic Advances in Respiratory Disease, 12, 1-16. https://doi.org/10.1177/1753466618810192
|
[20]
|
Massanari, M., Nelson, H., Casale, T., et al. (2010) Effect of Pretreatment with Omalizumab on the Tolerability of Specific Immunotherapy in Allergic Asthma. The Journal of Allergy and Clinical Immunology, 125, 383-389.
https://doi.org/10.1016/j.jaci.2009.11.022
|
[21]
|
Kopp, M.V., Hamelmann, E., Zielen, S., et al. (2009) Combination of Omalizumab and Specific Immunotherapy Is Superior to Immunotherapy in Patients with Seasonal Allergic Rhinoconjunctivitis and Co-Morbid Seasonal Allergic Asthma. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology, 39, 271-279. https://doi.org/10.1111/j.1365-2222.2008.03121.x
|
[22]
|
刘玲, 周薇, 李灵慧. 奥马珠单抗治疗儿童过敏性疾病28例临床分析[J]. 中华实用儿科临床杂志, 2021, 36(12): 926-930.
|
[23]
|
Kopp, M.V., Hamelmann, E., Bendiks, M., et al. (2013) Transient Impact of Omalizumab in Pollen Allergic Patients Undergoing Specific Immunotherapy. Pediatric Allergy and Immunology: Official Publication of the European Society of Pediatric Allergy and Immunology, 24, 427-433. https://doi.org/10.1111/pai.12098
|
[24]
|
Milgrom, H., Berger, W., Nayak, A., et al. (2001) Treatment of Childhood Asthma with Anti-Immunoglobulin E Antibody (Omalizumab). Pediatrics, 108, E36. https://doi.org/10.1542/peds.108.2.e36
|
[25]
|
王雪艳, 刘长山, 王肖玲, 等. 抗IgE治疗与皮下免疫治疗在儿童过敏性哮喘中的联合应用[J]. 中华实用儿科临床杂志, 2021, 36(12): 941-945.
|